Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Smart drugs: Implications of student use

  • 582 Accesses

  • 1 Citations

Abstract

The use of Smart Drugs to enhance intelligence, improve memory and maximize cognitive functioning in healthy individuals has attracted the attention of the popular press. This paper discusses the implication of the nonmedical college student use of “nootropic” Smart Drugs, a class of pharmaceuticals legally available in other countries to treat diseases associated with mental decline or dysfunction. Nootropic drug use is compared to steroid use in a student population. In a survey of college students, 5% of the males reported casual use of a drug to increase their intelligence, enhance their memory and make them smarter: 2.5% of these students probably used a nootropic drug.

This is a preview of subscription content, log in to check access.

References

  1. Allain, H., Boyer, D., Kossman, L., & Lepine, J. P. (1990). Therapeutic target for cognition enhancers: Diagnosis and clinical phenomenology.Pharmacopsychiatry, 23(sup), 65–69.

  2. Alperovitch, A. (1989). Clinical trials in memory disorders: Objectives and methodology.Archives of Gerontology & Geriatrics, 207–214.

  3. Amaducci, L., Angst, J., Beck, P., & Benkert, D. (1992). Consensus conference on the methodology of clinical trials of “nootropics”.Pharmacopsychiatry, 23 171–175.

  4. Anshel, M. (1991). A survey of elite athletes on the perceived causes of using banned drugs in sports.Journal of Sport Behavior, 14 283–310.

  5. Bartus, R. (1990). Drugs to treat age-related neurodegenerative problems: The final frontier of medical science.Journal of the American Geriatrics Society, 38 680–695.

  6. Boffey, P.M. (1988, July 25).The New York Times.

  7. Brady, D. (1992, April 27). Fuel for thought.Maclean's, pp. 60–61.

  8. Buresova, O., & Bures, J. (1976). Piracetam-induced facilitation of interhemispheric transfer of visual information in rates.Psychopharmacologia, 46 93–102.

  9. Bylinsky, G. (1986, January 20). Medicine's next marvel: The memory pill.Fortune, pp. 68–71.

  10. Dean, W., & Morgenthaler, J. (1990). Smart drugs & nutrients: How to improve your memory and increase your intelligence using the latest discoveries in neuroscience. Santa Cruz: B&J Publications.

  11. Erlich, J. (1992, September). Brain gain: Drugs that boost intelligence.Omni, pp. 42–51.

  12. Finally, a drink that makes you smart. (1991, October 14).Newsweek, p. 64.

  13. Foltyn, P., Lucker, P., Schnetker, J., & Wetzelsberger, N. (1983). A test model for cerebrally active drugs as demonstrated by the example of the new substance aniracetam.Arzneimittel-forschung, 33 865–867.

  14. Frostl, W., & Maitre, L. (1989).Pharmacopsychiatry, 22(sup), 54.

  15. Gallai, V., Mazzotta, G., del Gatto, F., & Montesi, S. (1991). A clinical and neurophysiological trial on nootropic drugs in patients with mental decline.Acta Neurologica, 13(1), 1–12.

  16. Gough, D. (1989). Steroids in athletes: Is the edge worth the risk? A review and commentary.Journal of Alcohol and Drug Education, 35 28–34.

  17. Herrmann, W. (1991). Efficacy and clinical relevance of cognition enhancers.Alzheimer Disease & Associated Disorders, 5 7–12.

  18. Hough, R. (1992, October). Get smart (effectiveness of piracetam).Saturday Night, pp. 38–40.

  19. ICN Biomedicals, Inc. (1992–93). (Catalog). Irvine, CA: Author.

  20. Itoh, J., Nakeshima, T., & Kameyama, T. (1990). Utility of an elevated plus-maze for the evaluation of memory in mice: Effects of nootropics, scopalamine and electroconvulsive shock.Psychopharmacology, 101 27–33.

  21. Lamb, D. (1980). Anabolic steroids and strength and power related athletic events.Journal of Physical Education-Recreation, 51 58–59.

  22. LeGro, W. (1992, March/April). Thinking capsules.Men's Health, p. 48.

  23. Lloyd, E., & Pryor, J. (1992). [Virginia Consortium Alcohol and Other Drug Survey]. Unpublished raw data.

  24. Merlini, L., & Pinza, M. (1989). Trends in searching for new cognition enhancing drugs.Progress in Neuro-Psychopharmacology & Biological Psychiatry, 13(sup), 561–575.

  25. Mondadori, C., Bhatnagar, A., Borkowski, J., & Hausler, A. (1990). Involvement of a steroidal component in the mechanism of action of piracetam-like nootropics.Brain Research, 506 101–108.

  26. Mondadori, C., Ducret, T., & Borkowski, J. (1991). How long does “memory consolidation” take? New compounds can improve retention performance, even if administered up to 24 hours after the learning experience.Brain Research, 555 107–111.

  27. Nicholson, C. (1990). Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.Psychopharmacology, 101 147–159.

  28. Olton, D. S., & Wenk, L. (1990). The development of behavioral tests to assess the effects of cognitive enhancers.Pharmacopsychiatry, 23(sup), 49–51.

  29. Orenstein, P. (1992, March). Get smart?Mademoiselle, pp. 164–165.

  30. Purvis, A. (1992, June 8). Ultra think fast.Time, p. 80.

  31. Saleta, B., & Grunberger, J. (1984). The hypoxia model in human psychopharmacology: Neurophysiological and psychometric studies with aniracetam I.V.Human Neurobiology, 3 171–181.

  32. Saleta, B., Grunberger, J. & Linzmayer, L. (1980). Quantitative EEG and psychometric analyses in assessing CNS-activity of R013-5057 — a cerebral insufficiency improver.Methods and Findings in Experimental Clinical Pharmacology, 2 269–285.

  33. Sarter, M., Hagan, J., & Dudchenko, P. (1992). Behavioral screening for cognition enhancers.Psychopharmacology, 7 144–159.

  34. Sheaffer, R. (1992, Summer). Psychic vibrations.Skeptical Inquirer, pp. 364–365.

  35. ‘Smart drugs’ not smart. (1992, May).FDA Consumer, pp. 3–4.

  36. Stewart, D. (1992, May/June). A fast fix for slow thinkers.Health, p. 26.

  37. Tang, C. N., Shi, Q-Y, Katchman, A., & Lynch, G. (1991). Modulation of time course of fast EPSCs and glutamate channel kinetics by aniracetam.Science, 254 288–290.

  38. Wild, R. (1992, March/April). Maximize your brain power.Men's Health, pp. 44–49.

  39. Wilsher, C. R. (1986). Developmental dyslexia and the nootropic concept.Early Child Development and Care, 26 207–228.

  40. Wolf, G. (1991, September 5). Don't get wasted, get smart!Rolling Stone, pp. 59–60.

  41. Yesalis, C., Streit, A., & Vicary, J. (1989). Anabolic steroid use: indications of habituation among adolescents.Journal of Drug Education, 2 103–116.

Download references

Author information

Correspondence to E. Lloyd Ed.D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Canterbury, R.J., Lloyd, E. Smart drugs: Implications of student use. J Primary Prevent 14, 197–207 (1994). https://doi.org/10.1007/BF01324593

Download citation

Key words

  • Smart drugs
  • substance abuse
  • nootropics